Zobrazeno 1 - 10
of 447
pro vyhledávání: '"Jean Jacques Grob"'
Autor:
Michael R. Migden, Aaron S. Farberg, James Spencer, Felix Kiecker, Alexander Guminski, Kurt Gebauer, Carmen Loquai, Caroline Robert, Reinhard Dummer, Dirk Schadendorf, Axel Hauschild, Jean Jacques Grob, Nicholas Squittieri, Ramon Arntz, Serena Martelli, Joerg Dierlamm, Ralf Gutzmer
Publikováno v:
EJC Skin Cancer, Vol 2, Iss , Pp 100267- (2024)
Background: The Hedgehog inhibitor sonidegib had durable efficacy and a manageable safety profile in patients with locally advanced basal cell carcinoma (laBCC) through 42 months of the BOLT trial. In this analysis, we characterize the effects of 200
Externí odkaz:
https://doaj.org/article/0277892c7a0f46a6b13d7cc11cac7d96
Autor:
Joaquina C. Baranda, Debbie Robbrecht, Ryan Sullivan, Bernard Doger, Armando Santoro, Minal Barve, Jean‐Jacques Grob, Oliver Bechter, Maria Vieito, Maria Jose deMiguel, Dirk Schadendorf, Melissa Johnson, Clemence Pouzin, Cathy Cantalloube, Rui Wang, Jooyun Lee, Xiaofei Chen, Brigitte Demers, Amele Amrate, Giovanni Abbadessa, F. Stephen Hodi
Publikováno v:
Clinical and Translational Science, Vol 17, Iss 6, Pp n/a-n/a (2024)
Abstract SAR439459 (SAR'459), a “second‐generation” human anti‐transforming growth factor beta (TGFβ) monoclonal antibody, enhances the activity of immune checkpoint inhibitors. In this phase I/Ib study, we evaluated the safety, pharmacokine
Externí odkaz:
https://doaj.org/article/0d7ccfe237a8402d86c3353c80fd2923
Autor:
Åse Bratland, Eva Munoz-Couselo, Laurent Mortier, Osama Roshdy, Rene González, Jacob Schachter, Ana M. Arance, Florent Grange, Nicolas Meyer, Abhishek Jagdish Joshi, Salem Billan, Brett G. M. Hughes, Jean-Jacques Grob, Karthik Ramakrishnan, Joy Ge, Burak Gumuscu, Ramona F. Swaby, Ralf Gutzmer
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 12, Pp 3165-3180 (2023)
Abstract Introduction At first interim analysis of KEYNOTE-629, health-related quality of life (HRQoL) with pembrolizumab was stable or improved over 48 weeks in recurrent or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC). HRQoL results fr
Externí odkaz:
https://doaj.org/article/c25ae9485a674062bd066049630a8b43
Autor:
Debbie Robbrecht, Jean‐Jacques Grob, Oliver Bechter, Matteo Simonelli, Bernard Doger, Ivan Borbath, Marcus O. Butler, Tina Cheng, Patricia Martin Romano, Elvire Pons‐Tostivint, Massimo Di Nicola, Giuseppe Curigliano, Min‐Hee Ryu, Alejo Rodriguez‐Vida, Dirk Schadendorf, Elena Garralda, Giovanni Abbadessa, Brigitte Demers, Amele Amrate, Hong Wang, Joon Sang Lee, Robert Pomponio, Rui Wang
Publikováno v:
Clinical and Translational Science, Vol 17, Iss 2, Pp n/a-n/a (2024)
Abstract SAR439459, a ‘second‐generation’ human anti‐transforming growth factor‐beta (TGFβ) monoclonal antibody, inhibits all TGFβ isoforms and improves the antitumor activity of anti‐programmed cell death protein‐1 therapeutics. This
Externí odkaz:
https://doaj.org/article/28412427e6174db093de8737922fa32a
Autor:
Marguerite Kandel, Aurélie Bardet, Stéphane Dalle, Clara Allayous, Laurent Mortier, Bernard Guillot, Caroline Dutriaux, Marie-Thérèse Leccia, Sophie Dalac, Henri Montaudie, Philippe Saiag, Delphine Legoupil, Florence Brunet-Possenti, Jean-Philippe Arnault, Julie De Quatrebarbes, Marie Beylot-Barry, Eve Maubec, Thierry Lesimple, François Aubin, Jean-Jacques Grob, Florence Granel-Brocard, Pierre-Emmanuel Stoebner, Alain Dupuy, Brigitte Dreno, Stefan Michiels, Céleste Lebbe, Isabelle Borget
Publikováno v:
Current Oncology, Vol 29, Iss 12, Pp 9255-9270 (2022)
Nine drugs have been marketed for 10 years for the treatment of advanced melanoma (AM). With half of patients reaching a second line, the optimal sequence of treatments remains unclear. To inform policy-makers about their efficiency, we performed a c
Externí odkaz:
https://doaj.org/article/029219c40f474f67aac932d94f25d323
Autor:
Paolo A. Ascierto, Sanjiv S. Agarwala, Christian Blank, Corrado Caracò, Richard D. Carvajal, Marc S. Ernstoff, Soldano Ferrone, Bernard A. Fox, Thomas F. Gajewski, Claus Garbe, Jean-Jacques Grob, Omid Hamid, Michelle Krogsgaard, Roger S. Lo, Amanda W. Lund, Gabriele Madonna, Olivier Michielin, Bart Neyns, Iman Osman, Solange Peters, Poulikos I. Poulikakos, Sergio A. Quezada, Bradley Reinfeld, Laurence Zitvogel, Igor Puzanov, Magdalena Thurin
Publikováno v:
Journal of Translational Medicine, Vol 20, Iss 1, Pp 1-21 (2022)
Abstract Advances in immune checkpoint and combination therapy have led to improvement in overall survival for patients with advanced melanoma. Improved understanding of the tumor, tumor microenvironment and tumor immune-evasion mechanisms has result
Externí odkaz:
https://doaj.org/article/eceaa54ada8b4252a49fcbe967456d2a
Autor:
Paolo A. Ascierto, Michael B. Atkins, Alexander M. Eggermont, Jeffrey E. Gershenwald, Jean-Jacques Grob, Omid Hamid, Vernon K. Sondak, Jeffrey A. Sosman, Hussein A. Tawbi, Jeffrey S. Weber, Corrado Caracò, Iman Osman, Igor Puzanov
Publikováno v:
Journal of Translational Medicine, Vol 19, Iss 1, Pp 1-17 (2021)
Abstract The Great Debate session at the 2020 Melanoma Bridge virtual congress (December 3rd–5th, Italy) featured counterpoint views from experts on five specific controversial issues in melanoma. The debates considered whether or not innate immuni
Externí odkaz:
https://doaj.org/article/a6ed1cc2e48e427fb2e3f34087eb34fc
Autor:
Paolo A. Ascierto, Sanjiv S. Agarwala, Alexander Eggermont, Jeffrey E. Gershenwald, Jean-Jacques Grob, Omid Hamid, Olivier Michielin, Michael Postow, Igor Puzanov, Hassane M. Zarour, Corrado Caracò, Alessandro Testori
Publikováno v:
Journal of Translational Medicine, Vol 18, Iss 1, Pp 1-15 (2020)
Abstract The Great Debate session at the 2019 Melanoma Bridge congress (December 5-7, Naples, Italy) featured counterpoint views from experts on five topical issues in melanoma. These were whether to choose local intratumoral treatment or systemic tr
Externí odkaz:
https://doaj.org/article/4daede7f31dc4fb49579ddcb6b1f76b4
Autor:
Dirk Schadendorf, Hussein Tawbi, Evan J. Lipson, F. Stephen Hodi, Piotr Rutkowski, Helen Gogas, Christopher D. Lao, Jean-Jacques Grob, Andriy Moshyk, Jennifer Lord-Bessen, Melissa Hamilton, Shien Guo, Ling Shi, Sarah Keidel, Georgina V. Long
Publikováno v:
European Journal of Cancer. 187:164-173
Background: In the phase II/III RELATIVITY-047 trial, a novel fixed-dose combination (FDC) of nivolumab plus relatlimab (NIVO + RELA; a programmed death-1 and a lymphocyte-activation gene 3 inhibitor, respectively) significantly improved progression-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e63f0f4f8612f517dcdf203d0a5aa768
https://doi.org/10.1016/j.ejca.2023.03.014
https://doi.org/10.1016/j.ejca.2023.03.014
Autor:
James Larkin, Jeffrey Weber, Victoria Atkinson, Michael Millward, Ivan Marquez-Rodas, Luis de la Cruz-Merino, Helen Gogas, Paolo A Ascierto, Anna Maria Di Giacomo, Veerle de Pril, Vanna Chiarion-Sileni, Stephane Dalle, Leslie Fecher, Ana Arance, Jean-Jacques Grob, Nikhil I Khushalani, Michele Del Vecchio, Mario Mandala, C Lance Cowey, Michael Schenker, Petr Arenberger, Maurice Lobo
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Externí odkaz:
https://doaj.org/article/c281f8a682984c818531f79c5352985a